Similarly, this analysis showed poor predictive effects of accompanying plasma gene alterations on CNS-PFS in patients with EGFR T790M mutated NSCLC, indicating that additional gene alterations could also be a potential biomarker in CNS efficacy analysis. Here, EGFR is linked to non-small cell lung carcinoma.